Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Receivables (2016 - 2023)

Historic Receivables for Abeona Therapeutics (ABEO) over the last 13 years, with Q2 2023 value amounting to $5.6 million.

  • Abeona Therapeutics' Receivables fell 8012.0% to $5.6 million in Q2 2023 from the same period last year, while for Jun 2023 it was $5.6 million, marking a year-over-year decrease of 8012.0%. This contributed to the annual value of $6.0 million for FY2021, which is N/A changed from last year.
  • Abeona Therapeutics' Receivables amounted to $5.6 million in Q2 2023, which was down 8012.0% from $27.3 million recorded in Q3 2022.
  • Abeona Therapeutics' 5-year Receivables high stood at $28.2 million for Q2 2022, and its period low was $15000.0 during Q3 2019.
  • Moreover, its 5-year median value for Receivables was $5.8 million (2021), whereas its average is $10.2 million.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 9989.17% in 2019, then soared by 9323333.33% in 2020.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Receivables stood at $15000.0 in 2019, then surged by 93233.33% to $14.0 million in 2020, then plummeted by 57.14% to $6.0 million in 2021, then surged by 355.78% to $27.3 million in 2022, then plummeted by 79.52% to $5.6 million in 2023.
  • Its last three reported values are $5.6 million in Q2 2023, $27.3 million for Q3 2022, and $28.2 million during Q2 2022.